Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Cardiology

The Biology of the Leak: Understanding CPVT

At a Glance

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a genetic condition causing a "calcium leak" in heart cells. Triggered by adrenaline during physical or emotional stress, this leak disrupts the heart's electrical system, potentially causing dangerous and rapid heart rhythms.

To understand Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), it is helpful to think of the heart as an electrical machine powered by microscopic “calcium batteries.” In a healthy heart, calcium is stored securely and released only at the exact moment a heartbeat is needed. In CPVT, these stores have a “leak” that becomes dangerous when the body is under stress [1][2].

You can return to the Home Page for a high-level overview.

The Calcium Leak: A Faulty Gateway

Inside every heart cell is a storage tank called the sarcoplasmic reticulum (SR), which holds the calcium needed for the heart to contract. The Ryanodine Receptor (RyR2) acts as the gateway to this tank [2].

In people with CPVT, mutations in the genes that build or regulate this gateway cause it to become “leaky” [1]. This is often described as a gain-of-function mutation because the gateway is too active—it stays open when it should be closed [1][3].

Scientists have two main theories for why this happens:

  • The Threshold Problem: The gateway becomes hypersensitive. Even a small amount of calcium in the tank causes the gate to pop open prematurely [4][3].
  • The Unzipping Problem: Imagine the RyR2 gate is held shut by a molecular “zipper.” Mutations can weaken this zipper, allowing the gate to fall open during the heart’s resting phase [5][3].

Why Adrenaline is the Trigger

Catecholamines (such as adrenaline) are the body’s “fight or flight” chemicals. When you or your child runs, gets excited, or feels a sudden fright, the brain floods the heart with adrenaline [1].

In a healthy heart, adrenaline helps the heart beat stronger and faster. However, in CPVT, adrenaline signals certain enzymes (like PKA and CaMKII) to attach to the already-leaky RyR2 gateway [1][3]. This makes the leak significantly worse, causing a massive, uncontrolled spill of calcium [1].

This sudden spill creates a “glitch” in the heart’s electrical system called a Delayed Afterdepolarization (DAD) [1][6]. If enough cells have these glitches at the same time, it can trigger a dangerous, rapid heart rhythm (arrhythmia) that prevents the heart from pumping blood effectively [1][6]. (Read more about how this is measured in Testing and Diagnosis).

Genetic Inheritance Patterns

CPVT is a genetic condition, meaning it is caused by a “spelling error” in a person’s DNA. The two most common forms are distinguished by how they are passed down through families.

Gene Inheritance Pattern Typical Features
RYR2 Autosomal Dominant Only one parent needs to pass on the gene for the child to have the condition. Sometimes, it is a de novo mutation, meaning it started with the patient and neither parent has it [7][8].
CASQ2 Autosomal Recessive Both parents must carry a copy of the mutated gene for the child to be affected. This form is rarer and often appears earlier in childhood with more severe symptoms [7][9].
  • Autosomal Dominant (RYR2): There is a 50% chance each child of an affected parent will inherit the condition [7].
  • Autosomal Recessive (CASQ2 or TRDN): Typically, the parents show no symptoms but are “carriers.” There is a 25% chance for each child to inherit the condition [7].

Other Involved Genes

While RYR2 and CASQ2 are the most common, other genes can cause similar calcium leaks:

  • CALM1, CALM2, CALM3: These genes create a protein called calmodulin, which normally helps keep the RyR2 gateway stable. Mutations here can lead to a very severe form of CPVT [7][10].
  • TRDN: Mutations in the triadin gene can lead to “Triadin Knockout Syndrome,” which often includes other heart electrical issues alongside the CPVT-style calcium leak [7][9].

Understanding the specific genetic “blueprint” of the CPVT diagnosis is vital, as it helps doctors tailor the right combination of Treatment Strategies to stabilize those leaky gateways [11][12].

Common questions in this guide

What causes the calcium leak in CPVT?
In CPVT, a genetic mutation causes the Ryanodine Receptor (RyR2), which acts as a gateway for calcium in heart cells, to become too active and leak. This prevents the heart from properly storing and releasing calcium to maintain a steady heartbeat.
Why does adrenaline trigger CPVT symptoms?
Adrenaline is a stress hormone that tells the heart to beat faster. In people with CPVT, adrenaline makes the already-leaky calcium gateway even weaker, causing a massive calcium spill that creates dangerous electrical glitches in the heart.
How is CPVT inherited?
Most cases of CPVT involve the RYR2 gene, which only requires one parent to pass on the mutation. In rarer cases involving the CASQ2 gene, both parents must carry a copy of the mutation for a child to be affected.
Do both parents need to have the CPVT gene to pass it on?
No, for the most common form of CPVT linked to the RYR2 gene, only one parent needs to have the mutation to pass it on. Sometimes, the condition starts as a completely new genetic mutation in the patient that neither parent has.
What is a de novo mutation in CPVT?
A de novo mutation means the genetic spelling error responsible for CPVT started spontaneously with the patient. It was not inherited from either parent, but the patient can still pass the mutation on to their own future children.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific gene is affected (e.g., RYR2, CASQ2), and what does that mean for inheritance and my future risks?
  2. 2.Is my mutation 'de novo' (new), or should my parents, siblings, and children also be tested?
  3. 3.How exactly does my specific genetic mutation affect the way my heart handles calcium during stress?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    The Purkinje-myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT.

    Blackwell DJ, Faggioni M, Wleklinski MJ, et al.

    JCI insight 2022; (7(3)).

    PMID: 34990403
  2. 2

    Sudden death after inappropriate shocks of implantable cardioverter defibrillator in a catecholaminergic polymorphic ventricular tachycardia case with a novel RyR2 mutation.

    Itoh H, Murayama T, Kurebayashi N, et al.

    Journal of electrocardiology 2021; (69()):111-118 doi:10.1016/j.jelectrocard.2021.09.015.

    PMID: 34656916
  3. 3

    Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.

    Wleklinski MJ, Kannankeril PJ, Knollmann BC

    The Journal of physiology 2020; (598(14)):2817-2834 doi:10.1113/JP276757.

    PMID: 32115705
  4. 4

    CPVT-associated cardiac ryanodine receptor mutation G357S with reduced penetrance impairs Ca2+ release termination and diminishes protein expression.

    Liu Y, Wei J, Wong King Yuen SM, et al.

    PloS one 2017; (12(9)):e0184177 doi:10.1371/journal.pone.0184177.

    PMID: 28961276
  5. 5

    A guide to the 3D structure of the ryanodine receptor type 1 by cryoEM.

    Samsó M

    Protein science : a publication of the Protein Society 2017; (26(1)):52-68 doi:10.1002/pro.3052.

    PMID: 27671094
  6. 6

    The role of calcium homeostasis remodeling in inherited cardiac arrhythmia syndromes.

    Hamilton S, Veress R, Belevych A, Terentyev D

    Pflugers Archiv : European journal of physiology 2021; (473(3)):377-387 doi:10.1007/s00424-020-02505-y.

    PMID: 33404893
  7. 7

    Advances in the Molecular Genetics of Catecholaminergic Polymorphic Ventricular Tachycardia.

    Song J, Luo Y, Jiang Y, He J

    Frontiers in pharmacology 2021; (12()):718208 doi:10.3389/fphar.2021.718208.

    PMID: 34483927
  8. 8

    A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia.

    Kohli U, Aziz Z, Beaser AD, Nayak HM

    Pacing and clinical electrophysiology : PACE 2019; (42(8)):1146-1154 doi:10.1111/pace.13668.

    PMID: 30912151
  9. 9

    New Family With Catecholaminergic Polymorphic Ventricular Tachycardia Linked to the Triadin Gene.

    Rooryck C, Kyndt F, Bozon D, et al.

    Journal of cardiovascular electrophysiology 2015; (26(10)):1146-50 doi:10.1111/jce.12763.

    PMID: 26200674
  10. 10

    Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

    Gao J, Makiyama T, Yamamoto Y, et al.

    Circulation. Arrhythmia and electrophysiology 2023; (16(3)):e011387 doi:10.1161/CIRCEP.122.011387.

    PMID: 36866681
  11. 11

    Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.

    Bergeman AT, Lieve KVV, Kallas D, et al.

    Circulation 2023; (148(25)):2029-2037 doi:10.1161/CIRCULATIONAHA.123.064786.

    PMID: 37886885
  12. 12

    The Antiarrhythmic Mechanisms of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia.

    Li Y, Peng X, Lin R, et al.

    Frontiers in physiology 2022; (13()):850117 doi:10.3389/fphys.2022.850117.

    PMID: 35356081

This page explains the biology and genetics of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) for educational purposes. Always consult a cardiologist or genetic counselor to discuss your specific diagnosis and family risk factors.

Get notified when new evidence is published on Catecholaminergic polymorphic ventricular tachycardia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.